Turning a Targeting β-Catenin/Bcl9 Peptide Inhibitor into a GdOF@Au Core/Shell Nanoflower for Enhancing Immune Response to Cancer Therapy in Combination with Immune Checkpoint Inhibitors

Turning a Targeting β-Catenin/Bcl9 Peptide Inhibitor into a GdOF@Au Core/Shell Nanoflower for Enhancing Immune Response to Cancer Therapy in Combination with Immune Checkpoint Inhibitors

Combination administration is becoming a popular strategy in current cancer immunotherapy to enhance tumor response to ICIs. Recently, a peptide drug, a protein–protein interaction inhibitor (PPI), that disrupts the β-catenin/Bcl9 interaction in the tumoral Wnt/β-catenin pathway has become a promisi...

Full description

Bibliographic Details
Main Authors: Weiming You, Fang Ma, Zhang Zhang, Jin Yan
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Pharmaceutics
Subjects:
immunotherapy
drug delivery
β-catenin
Bcl9 peptide
nanotechnology
Online Access:https://www.mdpi.com/1999-4923/14/6/1306

Similar Items

Similar Items